Prime Medicine Peer Comparison
$3.71
$0.04
(1.09%)
As on 03-Sep-2026 16:07EDT
Market cap
$655 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Edit
| Prime Medicine | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
655 | 2,928 | 2,262 | 2,152 | 851 |
Revenue ($ Mln) |
4 | 450 | 120 | 549 | -- |
Net Profit ($ Mln) |
-187.89 | -188.21 | -57.50 | 17.88 | -175.85 |
Net Margin (%) |
-4,613.11 | -41.86 | -144.33 | 3.26 | -- |
RoE (%) |
-233.88 | -28.46 | -9.86 | 1.43 | -106.84 |
Price to Earnings |
-- | -- | -- | 123.80 | -- |
Price-To-Book |
0.33 | 4.96 | 4.15 | 1.71 | 5.68 |
Income Statement ($ Mln)
| Prime Medicine | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4.07 | 449.61 | 17.20 | 549.12 | 0.00 |
|
Cost of Revenue
|
47.72 | 195.71 | 5.13 | 548.01 | 12.78 |
|
Gross Profit
|
-2.69 | 269.08 | 12.07 | 212.72 | -17.67 |
|
Operating Expenses
|
154.75 | 517.90 | 74.51 | 35.89 | 176.86 |
|
Operating Profit (EBIT)
|
-196.52 | -264.00 | -62.44 | -34.78 | -181.14 |
|
Other Income
|
0.00 | 0.00 | -- | 0.00 | 0.00 |
|
Profit before Tax
|
-187.89 | -190.72 | -101.81 | 20.08 | -178.93 |
|
Provision for Tax
|
0.00 | -2.51 | 0.33 | 1.66 | -3.09 |
|
Profit after Tax (Net Income)
|
-187.89 | -188.21 | -102.14 | 17.88 | -175.85 |
|
Minority Interest
|
0.00 | 0.00 | -- | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | -- | 0.00 | 0.00 |
Liabilities ($ Mln)
| Prime Medicine | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
39.81 | 607.04 | 597.44 | 1,260.78 | 160.40 |
|
Minority Interest
|
0.00 | 0.00 | -- | 0.00 | 0.00 |
|
Non-Current Liabilities
|
177.54 | 39.17 | 84.62 | 186.25 | 8.50 |
|
Current Liabilities
|
31.69 | 428.58 | 102.63 | 275.21 | 54.30 |
|
Total Liabilities
|
342.73 | 1,172.38 | 784.68 | 1,753.10 | 233.72 |
Assets ($ Mln)
| Prime Medicine | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
152.24 | 160.76 | 580.33 | 183.02 | 21.30 |
|
Current Assets
|
96.80 | 914.04 | 204.35 | 1,553.41 | 201.90 |
|
Total Assets
|
342.73 | 1,172.38 | 784.68 | 1,753.10 | 233.72 |
|
Total Debt*
|
112.48 | 254.58 | 128.16 | 94.51 | 21.00 |
|
Net Current Assets
|
65.11 | 485.45 | 101.72 | 0.00 | 147.60 |
Cashflow ($ Mln)
| Prime Medicine | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-162.56 | -150.79 | -49.95 | -64.66 | -121.18 |
|
Cash Flow from Investing Activities
|
-108.76 | 307.87 | 0.12 | -29.41 | -1.37 |
|
Cash from Financing Activities
|
151.51 | 72.35 | 147.34 | 7.84 | 276.18 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Prime Medicine | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-93.29 | -18.15 | -15.42 | 41.92 | -130.25 |
|
ROE (%)
|
-233.88 | -28.46 | -18.95 | 1.43 | -106.84 |
|
ROA (%)
|
-63.28 | -12.55 | -14.05 | 0.66 | -74.77 |
|
EBIT Margin (%)
|
-4,613.11 | -41.09 | -- | -6.33 | -- |
|
Net Margin (%)
|
-4,613.11 | -41.86 | -593.92 | 3.26 | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | -- | -- | -- |
Growth Ratios
| Prime Medicine | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-17.90 | 5.10 | 1.91 | -8.81 | -1.00 |
|
EBIT Growth (%)
|
5.71 | 11.36 | -- | -76.55 | -45.21 |
|
Net Profit Growth (%)
|
5.71 | 11.44 | -16.13 | -96.17 | -43.04 |
|
EPS Growth (%)
|
28.69 | -1.87 | -0.02 | -96.17 | 7.30 |
|
Book Value Growth (%)
|
-52.32 | -25.05 | -- | 2.54 | 108.85 |
Valuation Ratios
| Prime Medicine | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-2.57 | -11.11 | -13.58 | 5.08 | -9.99 |
|
Price / Book Value
|
4.27 | 2.73 | 2.32 | 1.88 | 8.70 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-2.32 | -9.39 | -18.38 | -25.58 | -9.30 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Prime Medicine | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.21 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.23 | 0.40 | 0.10 | 0.02 | 0.09 |
|
Current Ratio
|
3.05 | 2.13 | 1.99 | 5.64 | 3.72 |
|
Quick Ratio
|
3.05 | 1.92 | 1.77 | 5.50 | 3.72 |
|
Interest Coverage
|
-- | -30.87 | -3.49 | -19.05 | -- |
Operating Efficiency Ratios
| Prime Medicine | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.00 | 16.23 | 86.44 | 21.41 | -- |
|
Asset Turnover
|
0.01 | 0.30 | 0.02 | 0.20 | 0.00 |
|
Receivable days
|
-- | 77.60 | 380.35 | 104.79 | -- |
|
Inventory Days
|
-- | 109.55 | 791.94 | 49.57 | -- |
|
Payable days
|
504.84 | 231.78 | 931.00 | 47.68 | 650.68 |
|
Cash Conversion Cycle
|
-- | -44.63 | 241.30 | 106.67 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
